Triple threat: immunotherapy and targeted drug join forces against esophageal cancer
NCT ID NCT07457528
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding two newer drugs—serplulimab (an immunotherapy) and nimotuzumab (a targeted therapy)—to standard chemoradiation before surgery can improve outcomes for people with resectable esophageal cancer. About 46 participants will receive the combination, then undergo surgery 6–8 weeks later. The main goal is to see if the tumor shrinks significantly (major pathological response) and how safe the regimen is.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- serplulimab (immunotherapy) and nimotuzumab (targeted therapy) plus chemotherapy and radiation
- What this could lead to
- If successful, this combination could improve the chance of eliminating the tumor before surgery, potentially leading to better long-term outcomes for esophageal cancer patients.
- What could go wrong
- This is a small, early-phase trial (46 people) with no control group, so results may not be definitive. Adding multiple drugs to chemoradiation also raises the risk of side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Institute & Hospital
RECRUITINGTianjin, Tianjin Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.